DF
ARCT icon

Dunhill Financial’s Arcturus Therapeutics ARCT Stock Holding History

Dunhill Financial’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-60
Closed -$1.39K – 915
2024
Q3 		$1.39K Hold
60
– – ﹤0.01% 762
2024
Q2 		$1.46K Hold
60
– – ﹤0.01% 631
2024
Q1 		$2.03K Hold
60
– – ﹤0.01% 495
2023
Q4 		$1.89K Buy
+60
New +$1.43K ﹤0.01% 466

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Dunhill Financial's ARCT Position: Q4 2024 in Review

Dunhill Financial sold out of Arcturus Therapeutics (ARCT) in Q4 2024, closing a stake of 60 shares — an estimated $1.39K sold.

Dunhill Financial first reported a position in ARCT in Q4 2023 and held it in 4 quarters. The position peaked at $2.03K in Q1 2024. 148 funds tracked by Wall St. Rank hold ARCT as of Q4 2024.

  • Dunhill Financial reported no remaining Arcturus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Dunhill Financial sold 60 Arcturus Therapeutics shares in Q4 2024, an estimated $1.39K.
  • Dunhill Financial first reported a position in Arcturus Therapeutics in Q4 2023 and held it in 4 quarters.
  • Dunhill Financial's Arcturus Therapeutics position peaked at $2.03K in Q1 2024.
  • 148 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2024.

Based on Dunhill Financial's 13F filing for Q4 2024, filed 14 Feb 2025.